We have attempted to determine whether interleukin-5 (IL-5). a cytokine that selectively affects eosinophil (as opposed to neutrophil) differentiation and activation, also modulates eosinophil migrational responses. Using a modified Boyden chemotaxis assay, IL-5, IL-3, and granulocytemacrophage colony-stimulating factor (GM-CSF) gave a weak locomotory response for eosinophils from normal nonatopic subjects (optimal at lo-'', and mol/L, respectively), but not for eosinophils from subjects with an eosinophilia associated with asthma and/or allergic rhinitis. In contrast, IL-5 and IL-3 had no effect on neutrophils, while GM-CSF was chemotactic for neutrophils over a limited concentration range, optimal at mol/L. When eosinophils from normal subjects were incubated with IL-5 mol/ L), the locomotory response to platelet-activating factor (PAF; mol/L, P < .05), leukotriene B4 (LTB,; mol/L, P < .Ol), and N-formyl-methionyl-leucyl-phenylala-LOOD AND LOCAL tissue eosinophilia are recog-
and mol/L, respectively), but not for eosinophils from subjects with an eosinophilia associated with asthma and/or allergic rhinitis. In contrast, IL-5 and IL-3 had no effect on neutrophils, while GM-CSF was chemotactic for neutrophils over a limited concentration range, optimal at mol/L. When eosinophils from normal subjects were incubated with IL-5 mol/ L), the locomotory response to platelet-activating factor (PAF; mol/L, P < .05), leukotriene B4 (LTB,; mol/L, P < .Ol), and N-formyl-methionyl-leucyl-phenylala-LOOD AND LOCAL tissue eosinophilia are recog-B nized features of bronchial asthma, atopic allergy, helminthic infestations, and various malignant disorders.l.2 Through their ability to release granule-associated basic proteins and membrane-derived proinflammatory mediators, eosinophils have been implicated as major effector cells in the pathogenesis of allergic d i~e a s e .~-~ However, it remains unclear which mediators regulate the preferential recruitment and persistence of eosinophils at the site of allergic tissue reactions. A number of inflammatory agents have appreciable eosinophil chemotactic activity, including complement fragment 5a (C5a)6 and platelet-activating factor (PAF). 7 In addition, we have recently shown that in the guinea pig leukotriene B4 (LTI3,) and, to a lesser extent, 8(S)15(S)-diHETE8 constitute a majority of the activity originally termed the "eosinophil chemotactic factor of anaphylaxis" (ECF-A)? However, none of these mediators exhibit eosinophil selectivity. Although earlier studies suggested that a number of mast cell-derived mediators, including histamine,1° histamine catabolites,ll and acidic tetrapeptides (Val-and Ala-G1y-Ser-Glu),l2 appeared to have selective eosinophil chemotactic activity, it has now been shown that these factors have negligible effects compared with PAF. 7 The relationship between T lymphocytes and eosinophils
mol/L, P < .Ol) was significantly enhanced.
The percentage enhancement of eosinophil locomotion by IL-5 was greater for eosinophils from normal as compared with subjects with an eosinophilia associated with asthma (P < .05 for PAF and LTB, ; P < .01 for FMLP). Preincubation of eosinophils from normal subjects with IL-5 (1O-O mol/L) attenuated the subsequent locomotory response to IL-5
and lop1' mol/L, P < .05). Therefore, the obsewed refractoriness of eosinophils from eosinophilic subjects to both directional migratory and priming effects of IL-5 in vitro, may reflect a deactivation process resulting from prior exposure in vivo. The selective priming of eosinophil but not neutrophil locomotion by IL-5 suggests that this cytokine may play a significant role in the preferential accumulation of eosinophils at sites of allergic inflammation. 0 1992 by The American Society of Hematology.
has long been e~tab1ished.l~ Several studies have described human mononuclear cell-derived factors chemotactic for eosinophils in the context of parasitic infection.14J5 Similar activities were found to be released spontaneously from T lymphocytes isolated from the sputum of asthmatic patien@ and from lymphocytes isolated from normal donors stimulated with specific antigen.17 These activities, for the large part, remain chemically ill-defined and thus their possible role in asthma-and eosinophil-related diseases awaits clarification. Nevertheless, there is increasing evidence that activated T lymphocytes are a feature of allergic In support of this, it was recently reported that allergen-induced late-phase cutaneous reactions are characterized by the expression of messenger RNA (mRNA) for interleukind (IL-5), IL-4, IL-3, and granulocyte-macrophage colony-stimulating factor (GM-CSF)?l reminiscent of the murine Th2 profile of cytokines.22 The expression of mRNA for IL-5, found in bronchial biopsies from symptomatic asthmatics but not normal controls, correlated with severity of disease as measured by degree of infiltration of the bronchial mucosa by secreting (EG2+) eosinophils and activated (CD25+) T lymph0cytes.2~
In the present study, we have attempted to establish whether cytokines, particularly IL-5 with its highly selective effect on eosinophil differentiation, adhesion, and effector modulate eosinophil migratory responses. The effect of incubation with IL-5 on the subsequent chemotactic responsiveness of eosinophils to well-characterized chemoattractants was also studied. Because eosinophils from eosinophilic subjects may have been preexposed to cytokines in vivo, we compared the locomotory and priming effects of IL-5 for eosinophils isolated from normal and asthmatic subjects. We report that IL-5 exhibited selective locomotory and priming effects for eosinophilis purified from normals but not eosinophilic subjects. Patients. Peripheral blood leukocytes were obtained from two groups of volunteers grouped primarily on the basis of their atopic status: (1) 12 normal healthy nonatopic subjects with a peripheral blood eosinophilia ranging between 2% and 5%, with a median of 3% of the total leukocytes (0.11 x 109/L to 0.37 X lo9& median, 0.22 x 109/L); and (2) atopic subjects with differential eosinophil counts (above the normal range) between 8% and 48%, with a median of 12% of the total leukocytes (0.4 X 109/L to 13.4 x lo9/ L; median, 0.84 x 109/L) secondary to well-documented mild atopic asthma and/or allergic rhinitis. Atopy was defined on the basis of positive skin prick test reactions to a panel of common aeroallergens allergens, including housedust mite (Demtophagoide pteronyssinus), animal danders, and grass pollen. The eosinophilic asthmatic subjects were receiving intermittent PZagonist and low-dose inhaled corticosteroids. None of the patients were currently receiving oral corticosteroids during the period of this study.
Heparinized (20 U/mL) peripheral blood was separated by sedimentation of erythrocytes with dextran (4 parts b1ood:l part dextran) for 30 minutes at 37°C. The leucocyte-rich plasma was recovered and washed twice in RPMI-1640 supplemented with HEPES (30 mmol/L) before cellular purification on discontinuous density gradients. Eosinophils from eosinophilic patients were isolated by a standard 5-step metrizamide discontinuous gradient procedure.z7 After centrifugation at 1,200g for 45 minutes at 20"C, normal density eosinophils were recovered from the 22%/23%/25% interfaces (specific gravity, > 1.12 mg/mL). The cells were washed once in cold RPMI-1640 and residual erythrocytes lysed with ice-cold lysis buffer (NH4C1, 8.2 g, and KHC03, 1.0 g, in 1 L, pH 7.4) and finally washed twice in RPMI-1640 containing 4.0 mg/mL OA (250 g for 10 minutes at 4°C). Eosinophil counts on whole blood and isolated cells were performed using Kimura stain.z8 The recovery of eosinophils by this method was 27% -t 8%, with a purity of 90% 2 4% (n = 10). The main contaminating cell type was neutrophils.
Although the purity of normodense eosinophils recovered from metrizamide gradients was substantially greater than that obtained using Percoll gradients (see below), the recovery from normal donors by the former method yielded insufficient numbers of eosinophils for the microchemotaxis assay. Therefore, isolation of eosinophils and neutrophils from normal donors was performed on Percoll discontinuous gradients, using a modification of a previously described method.29 Briefly, cells from the leukocyte-rich plasma were resuspended in 1.5 mL of Percoll (1.080 g/mL density) containing 2.5 mg/mL BSA and overlayered onto a discontinuous gradient composed of Percoll solutions of the following densities and volumes: 1.120 (1 mL), 1.100 (3 mL), 1.095 (3 mL), 1 .090 (3 mL), and 1.085 (2 mL). The osmolality of 90% Percoll (9 parts, 100% Perco1l:l part 1OX Hanks' Balanced Salt Solution [HBSS] used to make the various density gradient fractions was adjusted to 313 to 315 mOsm/kg HzO with a solution of Percoll/HBSS (9 parts 100% Percolkl part 1X HBSS).% After centrifugation at 1,500g for 20 minutes at 20"C, normodense Purification of eosinophils and neutrophils. eosinophils were recovered from fractions with density 2 1.095 g/mL and neutrophils from the 1.090/1.095 g/mL interface and treated in the same way as described above. The recovery of normodense eosinophils from normal donors by this method was 40% -t 5% with a purity of 75% +. 5% (mean 2 SEM) (n = 10). The main contaminating cell type was neutrophils.
Locomotion was assessed by a modification of the Boyden chamber assay31 using 48-well microchemotaxis chambers (Neuro Probe, Inc, Cabin John, MD), as previously described. 32 In brief, cells were adjusted to 4 x W/mL in RPMI-1640 containing 4.0 mg/mL OA (pH 7.4) and 50 pL was placed in the upper well separated from 29 pL of chemoattractant in the lower well by an 8-pm nitrocellulose filter (Sartorius Instruments Ltd, Belmont, Surrey, UK). PAF and LTB4 stock solutions stored in solution at -80°C in chloroform/methanol and methanol, respectively, were evaporated to dryness over nitrogen and redissolved in RPMI-1640 plus 2.5 mg/mL BSA (pH 7.4) immediately before use. FMLP and all the cytokines used in this assay were also dissolved in this buffer. All assessments were performed in duplicate and diluent control was included in each assay. The multiwell chambers were placed in a moist-box to minimize evaporation and incubated for an optimal period of 90 minutes at 37"C, previously determined for nitrocellulose filter^.^,^^ The filters were washed in distilled water, fixed with saturated mercuric chloride/ethanol(50:50) solution, and stained with acidified hematoxylin/chromotrope 2R following a previously described method." Staining with chromotrope 2R was used to distinguish eosinophils from any contaminating neutrophils present. The cellular migrational response was determined by counting the number of cells that had migrated through to the underside of the filter in an area defined by a 10-mm eyepiece graticule in a light microscope using 400X magnification. Results were expressed as the number of cells counted in 10 random high power fields (hpf).
Cells at a final concentration of 4 x 106/mL in RPMI-1640 plus 4 mg/mL OA were incubated with increasing concentrations of IL-5 (10-lo to 2 X mol/L) for 60 minutes at 37°C. The cell suspensions were washed once with RPMI-1640 (25Og for 5 minutes at 20°C), resuspended in assay buffer, and the locomotory responses to PAF mol/L), LTB4 mol/L) assessed in the microchemotaxis assay. To determine the selectivity of IL-5 priming, the effects of incubation with IL-5 on the subsequent locomotory responsiveness of eosinophils and neutrophils from normals donors (n = 5 ) and eosinophils from eosinophilic subjects (n = 10) were compared.
Statistical analysis. All data are presented as mean rt SEM. Data obtained for the locomotory response of eosinophils and neutrophils to cytokines were statistically analyzed using the two-tailed paired Student's t-test and Bonferroni's correction3s was made for multiple comparisons (Fig 1) . Two-way analyses of variance were used to analyze data obtained for IL-5 priming of locomotory responsiveness of eosinophils and neutrophils. A Mann-Whitney U test was used to determine statistical differences in the percentage enhancement of directional locomotion by IL-5 for eosinophils purified from normal and eosinophilic volunteers. sive to IL-5, effective between and mol/L and optimal at lo-" mol/L (P < .01) (Fig 1A) . In contrast, IL-5 had no effect on the locomotory response of eosinophils from eosinophilic subjects or of neutrophils purified from normal subjects. IL-3 and GM-CSF elicited weak locomotory responses for eosinophils from normal subjects (optimal at mol/L and mol/L, respectively; P < .OS) (Fig 1B,C) , but not for eosinophils from eosinophilic subjects. Although IL-3 produced a small neutrophil migrational response, this was not significantly greater than the diluent control value over a wide concentration range ( Fig  1C) . Unlike IL-5 and IL-3, GM-CSF elicited migrational responses by neutrophils isolated from normal subjects (optimal at mol/L, P < .05) (Fig 1C) . IL-4 had no effect on either eosinophils or neutrophils when tested over a dose range of to mol/L (data not shown). To compare these responses with that of a recognized potent eosinophil chemoattractant, cells were tested against PAF. We found that although eosinophils from normals were much less responsive to PAF than eosinophils from eosinophilic subjects, a maximal response to PAF was observed at mol/L (P < .01) for cells from both subject populations (Fig 1D) . Compared with PAF, IL-5, IL-3, and GM-CSF produced, at best, moderate locomotory responses by eosinophils from normal subjects.
RESULTS

In initial
To show that the observed chemotactic effects of IL-5, especially at low concentrations, were indeed specific and not due to a contaminant in the cytokine preparation, experiments were performed in the presence of an optimal neutralizing concentration of IG5 antiserum (data not shown). We found that in the presence of a 1:lO dilution of IL-5 antiserum, there was a complete abrogation of the chemotactic response of eosinophils from normal subjects to IL-5 but not PAF mol/L) or diluent control (Fig 2) . In an attempt to explain the lack of responsiveness of eosinophils from eosinophilic subjects to IL-5 on the basis of in vivo chemotactic deactivation, eosinophils from normal subjects were preincubated with IL-5 before assessing the subsequent locomotory response to IL-5. A substantial attenuation of the directional response to optimal chemotactic concentrations IL-5 was observed after this treatment (Fig 3) .
Control experiments were performed to determine whether the different isolation procedures may have contributed to the differential responses observed between eosinophils purified from normal and eosinophilic subjects. No significant difference was found between the response of eosinophils from eosinophilic subjects isolated on metrizamide and Percoll discontinuous gradients towards IL-5, IL-3, GM-CSF, and PAF (data not shown).
IL-5priming to P M , Li'B4 and FMLP. The highly selective nature of IL-Sleosinophil interaction led us to study its effect on the priming of eosinophils to established chemoattractants. In preliminary experiments, the effect of incubation with IL-5 on the locomotory responses to a range of doses of PAF to mol/L) showed that significant enhancement of eosinophil locomotion was only observed for suboptimal doses of PAF and mol/L) (data not shown). Preincubation of eosinophils isolated from normal subjects with IL-5 (10-lo to 2 x mol/L) for 60 minutes at 37°C resulted in a significant enhancement of the subsequent locomotory response to PAF mol/L, P < .05) and optimal concentrations of weaker chemoattractants such as LTB4 mol/L, P < .01) and FMLP mol/L, P < .01) (Fig 4) . The optimal priming concentration for IL-5 was mol/L, after incubation for 60 to 90 minutes (results of time course study not shown). Preincubation with IL-5 produced no significant enhancement of the locomotory response to diluent, discounting a possible chemokinetic effect of the cytokine on the subsequent directional response of eosinophils towards a number of chemoattractants (Fig 4) . Furthermore, priming effects of IL-5 were sustained after removal To further show the selectivity of IL-5, priming experiments were performed using neutrophils from normal subjects and eosinophils isolated from eosinophilic subjects. Under optimal conditions for eosinophil priming, IL-5 had no significant effect on neutrophil chemotaxis (Table 1) . Furthermore, IL-5 was found to have a preferential priming effect on eosinophils from normal subjects because it produced only a small but not significant enhancement of the locomotory response of eosinophils isolated from subjects with an eosinophilia (Table 1) . Longer periods of incubation with IL-5 (24 and 48 hours) did not increase the resultant locomotory responsiveness of eosinophils from eosinophilic donors beyond that observed after 60 minutes of exposure (data not shown). Table 2 shows that the different methods used for the purification of eosinophils did not account for the refractoriness of eosinophils from asthmatic donors to the priming effects of IL-5.
Comparing the priming potential of IL-5, we found that the percentage enhancement of eosinophil chemotaxis by IL-5 was significantly greater for eosinophils from normal subjects as compared with eosinophils from subjects with a peripheral blood eosinophilia to either PAF, LTB4, or FMLP (Fig 5) .
Selectivity of IL-Spriming.
DISCUSSION
We have compared the chemotactic activities of a range of cytokines with the documented chemoattractant PAF for eosinophils from eosinophilic and normal subjects. A number of cytokines (IL-1, IL-2, TNF-a, IFN-y, IL-3, IL-5, GM-CSF, and IL-4) tested over a wide concentration range had negligible chemotactic activity for eosinophils isolated from eosinophilic subjects, with no evidence of a dose- Table 1 Blood (1 00 mL) was drawn from asthmatic patients (n = 5), and 50 mL was subjected to cellularfractionation on Percoll and the other 50 mL to cellular fractionation on metrizamide density gradients. Normodense eosinophils recovered by both methods were primed with IL-5 mol/L for 60 minutes at 37°C). Using two-way analysis of variance, no significant difference was found in the chemotactic response of eosinophils isolated on Percoll as compared with metrizamide to PAF, LTB4, or FMLP either before or after preincubation with IL-5.
response effect. We considered the possibility that eosinophils from subjects with elevated blood eosinophil counts had been desensitized as result of preexposure in vivo to agents with eosinophilopoietic activity, especially 1L-5.% For this reason, nonatopic subjects with a blood eosinophil count within the normal range (<0.40 x 109/L)37 were studied. IL-5 had modest chemotactic activity for "normal" eosinophils as compared with PAF, producing a doseresponse effect that was optimal at mol/L. By comparison, IL-5 had no effect on neutrophils. In agreement with our data, IL-5 has been described as being chemotactic for eosinophils from normal but the activity was compared with FMLP, which is an extremely weak chemotactic agent for unstimulated eosinophils. IL-3 and GM-CSF were weakly chemotactic for eosinophils from normal subjects, but only GM-CSF exhibited significant chemotactic activity for neutrophils (Fig 1B and C) . Therefore, we found that, although the chemotactic effects of eosinophilactive cytokines were limited compared with that of PAF, the maximal activities of the cytokines were found at picomolar concentrations, in contrast to micromolar concentrations for PAF. Thus, the hematopoietic cytokines appear to have chemotactic activity at close to physiologic concentrations.39. 40 Eosinophils from subjects with an eosinophilia (range, 8% to 48%) were markedly more responsive to PAF in vitro than eosinophils from normal subjects (range, 2% to 5% eosinophilia), suggesting in vivo activation (Fig 1D) . The difference in medication is unlikely to account for the observed differences in migrational responsiveness. Atopic subjects in this study were receiving intermittent P2-agonist and low-dose inhaled corticosteroid treatment, neither of which would be likely to result in a significant effect on cell locomotion. Previous in vitro studies have shown that preincubation of eosinophils with a wide dose range of either salbutamol or dexamethasone (low3 to mol/L) for up to 6 hours had no significant effect on the subsequent In addition, we have shown that the different methods for cell purification did not influence the differential responsiveness of eosinophils from normal and eosinophilic subjects to IL-5 and PAF (Table 1) . Furthermore, eosinophils from both groups of donors were taken from the normal density layer of the respective gradients (metrizamide, > 1.12 g/mL; and Percoll, > 1.095 g/mL), thereby excluding the possibility of this observation being related to density!2 In agreement with our findings, previous studies show that normodense eosinophils isolated from patients with a peripheral blood eosinophilia are metabolically more active than eosinophils from normal subjects.42 For example, helminthotoxic activity" and respiratory burst activity"5 are enhanced, and eosinophils from allergic asthmatics show a greater chemotactic response to FMLP in vitro& and PAF in than eosinophils from normal subjects. This enhanced responsiveness appeared to be associated with conditions in which a selective eosinophilia had developed and not in diseases in which the overall number of cells, including eosinophils, was e l e~a t e d .~,~~ We hypothesize, therefore, that the stimulus for eosinophilia may be associated with priming of the cells for enhanced responsiveness.
IL-5 AND EOSINOPHIL LOCOMOTION
Recent in vivo studies have shown a selective enhancement of IL-5 levels in the sera of patients with elevated blood eosinophil counts associated with helminthic infections, idiopathic hypereosinophilic syndrome, and eosinophilia-myalgia ~y n d r o m e . 4~,~~-~~ To test the above hypothesis further, we determined whether IL-5 could selectively prime eosinophils from normal subjects for an enhanced chemotactic response to PAF, LTB4, and FMLP. This was indeed the case (Fig 4) , although IL-5 alone was unable to prime eosinophils from normals for a response to PAF as great as that seen in cells isolated from eosinophilic subjects ( Table 1) . The optimal priming dose of IL-5 mol/L) was 100-fold greater than the amounts of IL-5 measured in the sera of Onchocercae-infected patients during the onset of eosinophilia.40 However, no published data are available on the absolute concentration of IL-5 in asthmatic sera, although the presence of this activity at picomolar concen-
trations was suggested by Walker et al.39 These findings raise the possibility that other eosinophilopoietic cytokines may be involved in the priming of eosinophils in vivo. In this regard, IL-3 and GM-CSP9 have been shown to prime eosinophils for increased chemotactic responses to PAF and LTB4 over a narrow dose range, comparable with that reported in this In human bone marrow cultures, IL-5 has an additive effect when combined with IL-3 or GM-CSF on the selective production of eosinophil colon i e~.~~ Because IL-5, IL-3, and GM-CSF are detectable in the sera of asthmatic patients with a mild eo~inophilia,3~ it is plausible that these factors may have an additive effect on the enhancement of eosinophil effector function, including chemotaxis. The mechanism of priming by cytokines may be associated with the induction of increased expression of high-affinity receptors for the ~hemoattractant.~~ In addition, Weisbart et aP3 reported that prolonged incubation of neutrophils with GM-CSF resulted in the emergence of low-affinity receptors for FMLP, concomitant with the loss of enhanced chemotactic responses to FMLP. This may possibly explain the "high-dose inhibition" phenomenon observed in the present study (Fig 4) .
The percentage enhancement of eosinophil locomotion by IL-5 was found to be significantly greater for eosinophils isolated from normal subjects as compared with eosinophils from subjects with an eosinophilia associated with a variety of conditions, including asthma (Fig 5) . The observed refractoriness of eosinophils from the latter group to IG5 in vitro may reflect a deactivation process resulting from prior exposure in vivo. Our data show that there was Some evidence of chemotactic deactivation to IL-5 in vivo in eosinophils from eosinophilic donors (Fig lA) , which we were able to mimic in vitro by preincubating normal eosinophils with IL-5 before assessment of the subsequent locomotory response to IL-5 (Fig 3) . In the same way, it has previously been shown that mature eosinophils from human bone marrow cells cocultured with IL-5 are less responsive to potentiation of their cytotoxic capacity by a further stimulation with IL-554 as compared with eosinophils freshly isolated from normal s~bjects.5~ These results suggest a role for IL-5 in the enhancement of eosinophil effector functions observed in cells isolated from eosinophilic pat i e n t~.~-~~ The capacity of IL-5 to prime eosinophils in directional locomotion suggests that this cytokine may have a crucial influence on the preferential accumulation of this cell type in allergic inflammation. The selective regulation of IL-5 may therefore offer an alternative approach to the control of eosinophilic bronchial inflammation in asthma.
In conclusion, we found that a range of cytokines had weak or negligible eosinophil chemotactic activity. Eosinophils from eosinophilic subjects are markedly primed in vivo in their responsiveness to PAF, LTB4, and FMLP compared with eosinophils from normal subjects. This priming may be due in part to IL-5, which is an effective and selective priming agent for eosinophil chemotaxis to PAF and weaker chemotactic agents such as FMLP and LTB4.
